Asthma progression: Can we and should we measure it? - 15/08/11
Doi : 10.1016/j.jaci.2007.12.1192
Stanley J. Szefler, MD ⁎ 
Divisions of Pediatric Clinical Pharmacology and Allergy and Immunology, Department of Pediatrics, National Jewish Medical and Research Center, and the Department of Pediatrics and Pharmacology, University of Colorado Health Sciences Center, Denver, Colo
Reprint requests: Stanley J. Szefler, MD, National Jewish Medical and Research Center, 1400 Jackson St, Rm J313, Denver, CO 80206.
Le texte complet de cet article est disponible en PDF.
Plan
| Supported in part by Public Health Services Research Grants 1NO1-HR-16048, HL36577, HL 51834, HL64288, and AI-25496 and General Clinical Research Center Grant 5 MO1 RR00051 from the Division of Research Resources. |
|
| Disclosure of potential conflict of interest: S. J. Szefler has consulting arrangements with AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received research support from Ross Pharmaceuticals, the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute. |
© 2008
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 121 - N° 3
P. 598-600 - mars 2008 Retour au numéro
Article précédent
- Guide for interpreting reports from inspections/investigations of indoor mold
- W. Elliott Horner, Charles Barnes, Rosa Codina, Estelle Levetin
- What the 21st century does not know about asthma—yet
- Charles E. Reed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?